摘要
目的探究重组牛碱性成纤维细胞生长因子滴眼液(贝复舒)联合玻璃酸钠滴眼液治疗干眼症的临床疗效。方法选取2018年3月~2019年3月在我院诊治的82例干眼症患者为研究对象,采用随机数字表法分为对照组和观察组,各41例。对照组采用玻璃酸钠滴眼液治疗,观察组在对照组基础上联合应用重组牛碱性成纤维细胞生长因子滴眼液治疗,比较两组临床治疗总有效率、临床症状评分、泪膜破裂时间、泪液分泌试验、荧光素染色评分以及临床不良反应发生情况。结果观察组治疗总有效率(95.12%)高于对照组(82.92%)(P<0.05);治疗后两组临床症状评分、荧光素染色评分均低于治疗前,泪膜破裂时间、泪液分泌试验均长于治疗前,且观察组优于对照组(P<0.05);两组均未发生严重不良反应。结论重组牛碱性成纤维细胞生长因子滴眼液联合玻璃酸钠滴眼液治疗干眼症有效率高,可有效改善患者临床症状,且不良反应少,用药安全,值得临床应用。
Objective To investigate the clinical efficacy of recombinant bovine basic fibroblast growth factor eye drops(Beifushu)combined with sodium hyaluronate eye drops in the treatment of xerophthalmia.Methods 82 patients with dry eye diagnosed and treated in our hospital from March 2018 to March 2019 were selected as the research objects,and the random number table method was used to divide them into control group and observation group,with 41 cases in each group.The control group was treated with sodium hyaluronate eye drops,and the observation group was combined with recombinant bovine basic fibroblast growth factor eye drops treatment on the basis of the control group.The clinical efficacy of the two groups,clinical symptom score,tear film rupture time,tear secretion test,and fluorescein staining were compared Score and occurrence of clinical adverse reactions.Results The total effective rate in the observation group(95.12%)was higher than that in the control group(82.92%)(P<0.05).After treatment,the clinical symptom scores and fluorescein staining scores of the two groups were lower than those before treatment.Membrane rupture time and tear secretion test were longer than before treatment,and the observation group was better than the control group(P<0.05);no serious adverse reactions occurred in both groups.Conclusion Recombinant bovine basic fibroblast growth factor eye drops combined with sodium hyaluronate eye drops is effective in treating xerophthalmia,and can effectively improve the clinical symptoms of patients with fewer adverse reactions and safe medication,which is worthy of clinical application.
作者
黑璐宁
高晨明
刘增业
HEI Lu-ning;GAO Chen-ming;LIU Zeng-ye(Department of Ophthalmology,Tianjin First Central Hospital,Tianjin 300192,China)
出处
《医学信息》
2020年第3期142-143,共2页
Journal of Medical Information
关键词
重组牛碱性成纤维细胞生长因子
玻璃酸钠滴眼液
干眼症
Recombinant bovine basic fibroblast growth factor
Sodium hyaluronate eye drops
Xerophthalmia
作者简介
黑璐宁(1983.3-),女,天津人,本科,技师,主要从事眼科特检工作。
